weak),
Quality of Evidence: C (low to very low)

Table XXIV. Treatment of superﬁcial venous thrombosis
First author, Year

Patients/Limbs

Intervention

DiNisio
201834

7296

Fondaparinux,
rivaroxaban, LMWH,
unfractionated
heparin, NSAIDS,
compression,
topical, IM, IM,
surgical

Duffett
201935

6862

Prandoni, 2022255

Casian,
2022256

Comparison

Outcome

Study design

Placebo (few)

SVT extension, VTE,
pain, bleeding

RCTs for
systematic review

NSAIDs,
anticoagulant
therapies, surgical
therapies

Placebo, No
therapy (few)

DVT, PE

RCT, cohort for
Systematic review

374

LMWH,
fondaparinux, VKA,
DOAC (full
anticoagulation)

Preventive
anticoagulation

SVT extension, VTE,
bleeding

Retrospective,
registry

190/195

Anticoagulation,
surgery

None

SVT recurrence,
extension, VTE

Prospective
observational

DOAC, Direct oral anticoagulant; LMWH, low-molecular-weight heparin; NSAID, nonsteroidal anti-inﬂammatory drug; PE, pulmonary embolism; RCT,
randomized controlled trial; SVT, superﬁcial vein thrombosis; VKA, vitamin K agonist; VTE, venous thromboembolism.

38

Gloviczki et al

Journal of Vascular Surgery: Venous and Lymphatic Disorders
January 2024

8.1.3. For patients with symptomatic reﬂux in the GSV
or SSV, we suggest ablation of the reﬂuxing venous
trunk and staged phlebectomy or UGFS of the varicosities only if anatomical or medical reasons are present.
We suggest shared decision-making with the patient
regarding timing of the procedure.
GUIDELINE: Grade of recommendation: 2 (weak),
Quality of Evidence: C